Gladstone in the News
December 15, 2021
The Conversation—Individuals who survive traumatic brain injury can suffer from life-long complications, such as cognitive deficits, seizures, and sleep disruption. Jeanne Paz, PhD, describes her work in mice showing that treatment with an antibody that blocks an element of immune system activation may be able to prevent such consequences.
Gladstone Experts
Traumatic Brain Injury
Neurological Disease
Paz Lab
Gladstone in the News
December 15, 2021
abc7 NEWS—Senior Investigator Leor Weinberger, PhD, and Research Investigator Sonali Chaturvedi, PhD, explain their work on a therapy that sharply reduces viral load in the nose of hamsters after a single administration and could add a promising new tool to the therapeutic arsenal against COVID-19.
Gladstone Experts
COVID-19
Virology
Weinberger Lab
Gladstone in the News
December 14, 2021
San Francisco Business Times—Senior Investigator Leor Weinberger, PhD, pioneered a new class of antivirals called therapeutic interfering particles (TIPs), which were recently shown to be effective against SARS-CoV-2 in animal models. The approach is now being developed by a startup company and will be headed to clinical trials.
Gladstone Experts
COVID-19
Center for Cell Circuitry
Virology
Weinberger Lab
Gladstone in the News
December 14, 2021
San Francisco Chronicle—The omicron variant of SARS-CoV-2 is spreading rapidly, but it may not be a reason for panic. Nadia Roan explains that our immune system’s cellular response to the vaccines should hold up well against the omicron variant. In addition, Warner Greene predicts that if the variant spreads rapidly but causes just mild disease, it might actually help establish immunity globally, protecting people in places where vaccine access has been limited.
Gladstone Experts
COVID-19
Greene Lab
Roan Lab
Gladstone in the News
December 6, 2021
San Francisco Chronicle—The identification of an individual infected with the Omicron variant of SARS-CoV-2 in San Francisco is helping local scientists assess the danger posed by the virus. Melanie Ott, director of the Gladstone Institute of Virology, explains that experiments using virus samples from that individual could help determine how well the available vaccines hold up to Omicron’s mutations.
Gladstone Experts
COVID-19
Virology
Ott Lab
Gladstone in the News
December 1, 2021
Brain Injury Radio—On a radio show dedicated to traumatic brain injury (TBI), Associate Investigator Jeanne Paz, PhD, explains her life-long interest and current work in TBI and in epilepsy, a common long-term consequence of brain damage.
Gladstone Experts
Traumatic Brain Injury
Epilepsy
Paz Lab
Gladstone in the News
December 1, 2021
San Francisco Chronicle—The emerging Omicron variant of SARS-CoV-2 features several mutations in its spike protein that in theory could make it resistant to current vaccines. But Associate Investigator Nadia Roan, PhD, explains that current vaccines will still protect against Omicron, as they elicit a variety of antibodies and immune T cells that target non-mutated areas of spike.
Gladstone Experts
COVID-19
Virology
Roan Lab
Gladstone in the News
November 26, 2021
ABC News—A new variant of SARS-CoV-2, dubbed Omicron, is causing concern around the world. Gladstone President Deepak Srivastava explains that some of the variant’s 50 mutations may have arisen when an individual who was already immunocompromised became infected with the virus. Senior Investigator Nevan Krogan describes how his group is investigating whether the new mutations will change the ability of the virus to enter cells and cause disease.
Gladstone Experts
COVID-19
Data Science and Biotechnology
Virology
Krogan Lab
Srivastava Lab
Gladstone in the News
November 18, 2021
NIH Director’s Blog—The Delta variant of SARS-CoV-2 is driving the latest surge of COVID-19 cases in the United States. New research from Senior Investigators Jennifer Doudna and Melanie Ott explains how mutations in this variant increase transmissibility.
Gladstone Experts
COVID-19
Virology
Doudna Lab
Ott Lab
Gladstone in the News
November 16, 2021
BioIT World—Despite decades of research, medical therapies for Alzheimer’s disease have so far proven elusive. Senior Investigator Yadong Huang describes how his innovative approach to drug repurposing has identified a promising candidate drug that is now moving toward clinical trials.
Gladstone Experts
Alzheimer’s Disease
Neurological Disease
Huang Lab
Gladstone in the News
November 9, 2021
ABC News—Traumatic brain injuries can result in sleep disruptions and seizures. Gladstone Associate Investigator Jeanne Paz describes her team’s recent identification of an immune molecule that may be key to these symptoms, and the potential to treat brain injury survivors with new therapies.
Gladstone Experts
Traumatic Brain Injury
Neurological Disease
Paz Lab
